<DOC>
	<DOC>NCT02580864</DOC>
	<brief_summary>Individuate possible predictive factors of anti-TNFalfa-induced deep remission in Crohn's disease.</brief_summary>
	<brief_title>Bologna IBD Markers</brief_title>
	<detailed_description>This trial will be exploratory, open in vitro study on human tissues. 120 patients will be enrolled (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease and with indication for anti-TNF therapy according to the normal clinical practice. Simultaneously, 30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic will be enrolled.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Main Inclusion Criteria for IBD patients: Adult patients (Caucasian) Moderatesevere active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) Indication for antiTNF therapy according to the normal clinical practice Informed consent signed Main Exclusion Criteria for IBD patients: Changes of Crohns disease treatment gastrointestinal medication (including corticosteroids) within the previous 2 weeks prior to enrollment Pregnant or breastfeeding (at index date) female patients Main Inclusion Criteria for noIBD controls: NoIBD adult controls (Caucasian) with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the outpatient clinic Informed consent signed Main Exclusion criteria for noIBD controls: Medical history of digestive diseases Digestive, renal or metabolic disease, as determined by the medical visit and sa blood chemistry analysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>